BACKGROUND AND PURPOSE: Histamine H3 receptor antagonists are currently being evaluated for their potential use in a number of central nervous system disorders including Alzheimer's Disease (AD). To date, little is known about the state of H3 receptors in AD. EXPERIMENTAL APPROACH: In the present study we used the radiolabelled H3 receptor antagonist [3H]GSK189254 to investigate H3 receptor binding in the amyloid over-expressing double mutant APPswe x PSI.MI46V (TASTPM) transgenic mouse model of AD and in post-mortem human AD brain samples. KEY RESULTS: No significant differences in specific H3 receptor binding were observed between wild type and TASTPM mice in the cortex, hippocampus or hypothalamus. Specific [3H]GSK189254 binding was detected in sections of human medial frontal cortex from AD brains of varying disease severity (Braak stages I-VI). With more quantitative analysis in a larger cohort, we observed that H3 receptor densities were not significantly different between AD and age-matched control brains in both frontal and temporal cortical regions. However, within the AD group, [3H]GSK189254 binding density in frontal cortex was higher in individuals with more severe dementia prior to death. CONCLUSIONS AND IMPLICATIONS: The maintenance of H3 receptor integrity observed in the various stages of AD in this study is important, given the potential use of H3 antagonists as a novel therapeutic approach for the symptomatic treatment of AD.
BACKGROUND AND PURPOSE:Histamine H3 receptor antagonists are currently being evaluated for their potential use in a number of central nervous system disorders including Alzheimer's Disease (AD). To date, little is known about the state of H3 receptors in AD. EXPERIMENTAL APPROACH: In the present study we used the radiolabelled H3 receptor antagonist [3H]GSK189254 to investigate H3 receptor binding in the amyloid over-expressing double mutant APPswe x PSI.MI46V (TASTPM) transgenic mouse model of AD and in post-mortem humanAD brain samples. KEY RESULTS: No significant differences in specific H3 receptor binding were observed between wild type and TASTPM mice in the cortex, hippocampus or hypothalamus. Specific [3H]GSK189254 binding was detected in sections of human medial frontal cortex from AD brains of varying disease severity (Braak stages I-VI). With more quantitative analysis in a larger cohort, we observed that H3 receptor densities were not significantly different between AD and age-matched control brains in both frontal and temporal cortical regions. However, within the AD group, [3H]GSK189254 binding density in frontal cortex was higher in individuals with more severe dementia prior to death. CONCLUSIONS AND IMPLICATIONS: The maintenance of H3 receptor integrity observed in the various stages of AD in this study is important, given the potential use of H3 antagonists as a novel therapeutic approach for the symptomatic treatment of AD.
Authors: E Perry; J Court; R Goodchild; M Griffiths; E Jaros; M Johnson; S Lloyd; M Piggott; D Spurden; C Ballard; I McKeith; R Perry Journal: J Neural Transm (Vienna) Date: 1998 Impact factor: 3.575
Authors: M Higuchi; K Yanai; N Okamura; K Meguro; H Arai; M Itoh; R Iwata; T Ido; T Watanabe; H Sasaki Journal: Neuroscience Date: 2000 Impact factor: 3.590
Authors: P Blandina; M Giorgetti; L Bartolini; M Cecchi; H Timmerman; R Leurs; G Pepeu; M G Giovannini Journal: Br J Pharmacol Date: 1996-12 Impact factor: 8.739
Authors: Rachael I Scahill; Jonathan M Schott; John M Stevens; Martin N Rossor; Nick C Fox Journal: Proc Natl Acad Sci U S A Date: 2002-04-02 Impact factor: 11.205
Authors: Paolo Onori; Eugenio Gaudio; Antonio Franchitto; Gianfranco Alpini; Heather Francis Journal: World J Gastrointest Pathophysiol Date: 2010-06-15
Authors: Ranjana Patnaik; Aruna Sharma; Stephen D Skaper; Dafin F Muresanu; José Vicente Lafuente; Rudy J Castellani; Ala Nozari; Hari S Sharma Journal: Mol Neurobiol Date: 2018-01 Impact factor: 5.590
Authors: Patrizia Giannoni; Andrew D Medhurst; Maria Beatrice Passani; Maria Grazia Giovannini; Chiara Ballini; Laura Della Corte; Patrizio Blandina Journal: J Pharmacol Exp Ther Date: 2009-10-08 Impact factor: 4.030
Authors: Mar Rodríguez-Ruiz; Estefanía Moreno; David Moreno-Delgado; Gemma Navarro; Josefa Mallol; Antonio Cortés; Carme Lluís; Enric I Canela; Vicent Casadó; Peter J McCormick; Rafael Franco Journal: Mol Neurobiol Date: 2016-07-01 Impact factor: 5.590
Authors: Goran Šimić; Mirjana Babić Leko; Selina Wray; Charles R Harrington; Ivana Delalle; Nataša Jovanov-Milošević; Danira Bažadona; Luc Buée; Rohan de Silva; Giuseppe Di Giovanni; Claude M Wischik; Patrick R Hof Journal: Prog Neurobiol Date: 2016-04-12 Impact factor: 11.685